#Acadia (ACAD)

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits outweigh the risks of Acadia’s (ACAD) drug  Nuplazid™  (pimavanserin) fo...

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine Alder Also Reports Positive Phase 1 Data Supporting Qu...

Onyx (ONXX)  continues to have good news . Bayer was used to benefit from Onyx’ drugs’ successes - the last was  Kyprolis ®  (carfilzomib) , a second-generation proteasome inhibitor for multiple myelo...

Acadia (ACAD):  The stock staged a rally -  more than tripled - in early trading. Results from its investigational drug pimavanserin, met the primary goal of reducing psychotic symptoms in a late-stag...